Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.

Our findings suggest that a substantial number of patients receiving first-/second-line vandetanib may sustain long clinical benefit and that a younger age at diagnosis and the absence of progression before treatment could be considered as predictors of durable response.